Gradientech expands its distribution network in Europe
The diagnostic company Gradientech today announces an exclusive distribution agreement with Iberlab for the commercialisation of QuickMIC® in Portugal.
Iberlab is a leading supplier of diagnostic solutions and consumables to clinical laboratories on the Portuguese market. “At Iberlab, we aim to meet our customers’ requirements at the highest level. It is our strong ambition to provide diagnostic solutions to satisfy the needs of the clinical laboratory. Adding the product line from Gradientech is therefore a strong addition to our portfolio. The QuickMIC system fits our focus perfect as we want to fight sepsis and provide the market with the faster solutions that can help save lives and contribute to reduced healthcare costs”, comments João Teixeira, CEO at Iberlab.
Gradientech already has exclusive distribution agreements for the commercialisation of QuickMIC with Biomedica in Austria and Central Eastern Europe and with the Triolab group in Sweden, Denmark, Norway, Iceland and the Baltics.
“We are very glad to present Iberlab as our exclusive distributor in Portugal. Portugal is an important market for us with the need of rapid susceptibility testing driven by the relatively high resistance levels in society. Iberlab has the drive, experience and expertise needed to successfully roll-out QuickMIC with the aim to make us market leaders of ultra-rapid antibiotic susceptibility testing in Portugal”, says Peter Karlberg, VP Sales at Gradientech.
The QuickMIC system’s ultra-rapid and precise results enable patients with sepsis to quickly receive specific personalised guidance of the right antibiotics in the right dose. The modular design of the system makes it possible for hospital labs to start on a small scale and expand with more modules depending on needs. The QuickMIC system and its Gram-negative panel are CE-marked and commercially available in Europe but not yet available for sale in the United States.
For further information, please contact:
Peter Karlberg, VP Sales Gradientech
Tel: + 46 763 29 08 14
Sara Thorslund, PhD, CEO Gradientech
Tel: +46 736 29 35 80
Gradientech is leading the field of ultra-rapid antibiotic susceptibility testing. We develop next-generation diagnostics in infectious disease medicine. Our product QuickMIC®, classified as a breakthrough device by the U.S. Food and Drug Administration, allows patients with sepsis to quickly receive specific guidance on the right antibiotic in the right dose. It saves lives, reduces healthcare costs and limits the spread of antibiotic resistance – one of the greatest global health threats of our time. Gradientech is headquartered in Uppsala, Sweden. Visit www.gradientech.se for more information.
IBERLAB’s mission is to satisfy the needs in diverse types of clinical laboratories, providing a wide range of diagnostic solutions adjusted to the needs and requirements of our customers. We believe that innovation, quality and competence are fundamental in for continued strong growth. Visit www.iberlab.pt for more information.
Next-generation antimicrobial susceptibility testingTake a look at our E-book